{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:25:43Z","timestamp":1794489943833,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor linking environmental signals to immune regulation and neurodegeneration. While AHR agonists exert protective effects in Alzheimer\u2019s disease (AD) models, their relevance in humans remains unclear. We investigated AHR agonistic activity in serum and cerebrospinal fluid (CSF) across AT1-defined AD subtypes and its association with amyloid beta (A\u03b2) metabolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We measured AHR agonistic activity using a luciferase reporter assay in serum and cerebrospinal fluid (CSF) from 138 individuals (113 non-demented, 25 demented) classified by CSF A\u03b21-42, A\u03b21-42\/A\u03b21-40 ratio and pTau181 into four AT1 groups: A\u2009+\u2009T1\u2009+\u2009(AD), A\u2009+\u2009T1- (isolated decrease of A\u03b21-42\/A\u03b21-40 or A\u03b21-42), A-T1\u2009+\u2009(isolated tau pathology\/PASSED), and A-T1- (biomarker-negative controls).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum AHR agonistic activity was significantly reduced in biomarker-positive individuals compared to controls (\u0394 z-score\u2009=\u20092.25, 95% CI [1.33, 3.17],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with the most pronounced reductions observed in two distinct phenotypes: non-demented A-T1\u2009+\u2009individuals (z-score\u2009=\u2009-2.33, 95% CI [-3.26, -1.40]) and A\u2009+\u2009T1\u2009+\u2009patients with preserved CSF A\u03b21-42 despite pathological A\u03b21-42\/A\u03b21-40 ratios (\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.006 compared to A\u2009+\u2009T1\u2009+\u2009with pathological A\u03b21-42). Serum AHR activity correlated negatively with CSF A\u03b21-40 (\u03c1\u2009=\u2009-0.31,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and A\u03b21-42 (\u03c1\u2009=\u2009-0.20,\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.021) across all participants. The relationship between pTau181 and serum AHR activity showed significant effect modification by amyloidopathy (A) (interaction\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001): negative in A- individuals (\u03b2\u2009=\u2009-0.54,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) but positive at high pTau181 levels in A\u2009+\u2009cases (\u03b2\u2009=\u20090.12,\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.025). CSF AHR activity showed no significant differences between AT1 groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Peripheral AHR agonistic activity is reduced in early and atypical AD phenotypes and correlates with amyloid peptides A\u03b21-42 and A\u03b21-40 in CSF. The amyloid status-dependent reversal of pTau181-AHR associations suggests distinct regulatory mechanisms across AT1 groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-026-01978-w","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:04:35Z","timestamp":1770357875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reduced serum AHR agonistic activity reflects amyloid dysregulation in AT1 subtypes of Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"18","author":[{"given":"Thanos","family":"Tsaktanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rudtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leander","family":"Ammon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Mestermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit","family":"Rothhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Lewczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Maler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kornhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo Jan","family":"Oberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"1978_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature10251","volume":"476","author":"International Multiple Sclerosis Genetics C","year":"2011","unstructured":"International Multiple Sclerosis Genetics C, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214\u20139.","journal-title":"Nature"},{"key":"1978_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.coi.2016.09.002","volume":"43","author":"V Rothhammer","year":"2016","unstructured":"Rothhammer V, Quintana FJ. Environmental control of autoimmune inflammation in the central nervous system. Curr Opin Immunol. 2016;43:46\u201353.","journal-title":"Curr Opin Immunol"},{"key":"1978_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/imm.12046","volume":"138","author":"FJ Quintana","year":"2013","unstructured":"Quintana FJ. The aryl hydrocarbon receptor: a molecular pathway for the environmental control of the immune response. Immunology. 2013;138:183\u20139.","journal-title":"Immunology"},{"key":"1978_CR4","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.smim.2015.10.002","volume":"27","author":"M Cella","year":"2015","unstructured":"Cella M, Colonna M. Aryl hydrocarbon receptor: linking environment to immunity. Semin Immunol. 2015;27:310\u20134.","journal-title":"Semin Immunol"},{"key":"1978_CR5","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nm.3868","volume":"21","author":"ID Mascanfroni","year":"2015","unstructured":"Mascanfroni ID, et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-alpha. Nat Med. 2015;21:638\u201346.","journal-title":"Nat Med"},{"key":"1978_CR6","doi-asserted-by":"publisher","first-page":"20768","DOI":"10.1073\/pnas.1009201107","volume":"107","author":"FJ Quintana","year":"2010","unstructured":"Quintana FJ, et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2010;107:20768\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1978_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature06880","volume":"453","author":"FJ Quintana","year":"2008","unstructured":"Quintana FJ, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature. 2008;453:65\u201371.","journal-title":"Nature"},{"key":"1978_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev.pharmtox.43.100901.135828","volume":"43","author":"MS Denison","year":"2003","unstructured":"Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol. 2003;43:309\u201334.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1978_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41577-019-0125-8","volume":"19","author":"V Rothhammer","year":"2019","unstructured":"Rothhammer V, Quintana FJ. The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease. Nat Rev Immunol. 2019;19:184\u201397.","journal-title":"Nat Rev Immunol"},{"key":"1978_CR10","doi-asserted-by":"publisher","first-page":"8797","DOI":"10.7150\/thno.61601","volume":"11","author":"C Qian","year":"2021","unstructured":"Qian C, et al. Activating AhR alleviates cognitive deficits of Alzheimer\u2019s disease model mice by upregulating endogenous A\u03b2 catabolic enzyme neprilysin. Theranostics. 2021;11:8797\u2013812.","journal-title":"Theranostics"},{"key":"1978_CR11","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20:5143\u201369.","journal-title":"Alzheimers Dement"},{"key":"1978_CR12","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1093\/brain\/awac297","volume":"145","author":"TJ Oberstein","year":"2022","unstructured":"Oberstein TJ, et al. Amyloid-\u03b2 levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy. Brain. 2022;145:4032\u201341.","journal-title":"Brain"},{"key":"1978_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nrneurol.2015.251","volume":"12","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, et al. Suspected non-Alzheimer disease pathophysiology\u2013concept and controversy. Nat Rev Neurol. 2016;12:117\u201324.","journal-title":"Nat Rev Neurol"},{"key":"1978_CR14","doi-asserted-by":"publisher","first-page":"1121500","DOI":"10.3389\/fnagi.2023.1121500","volume":"15","author":"AL Haas","year":"2023","unstructured":"Haas AL, et al. PASSED: Brain atrophy in non-demented individuals in a long-term longitudinal study from two independent cohorts. Front Aging Neurosci. 2023;15:1121500.","journal-title":"Front Aging Neurosci"},{"key":"1978_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00152","volume":"10","author":"P Spitzer","year":"2018","unstructured":"Spitzer P, et al. A specific reduction in A\u03b2(1\u201342) vs. a universal loss of A\u03b2 peptides in CSF differentiates Alzheimer\u2019s disease from meningitis and multiple sclerosis. Front Aging Neurosci. 2018;10:152.","journal-title":"Front Aging Neurosci"},{"key":"1978_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/1352458512460603","volume":"19","author":"K Augutis","year":"2013","unstructured":"Augutis K, et al. Cerebrospinal fluid biomarkers of \u03b2-amyloid metabolism in multiple sclerosis. Mult Scler. 2013;19:543\u201352.","journal-title":"Mult Scler"},{"key":"1978_CR17","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1212\/NXI.0000000000000359","volume":"4","author":"V Rothhammer","year":"2017","unstructured":"Rothhammer V, et al. Dynamic regulation of serum aryl hydrocarbon receptor agonists in MS. Neurol Neuroimmunol Neuroinflamm. 2017;4:e359.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1978_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4106","author":"V Rothhammer","year":"2016","unstructured":"Rothhammer V, et al. Type i interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med. 2016. https:\/\/doi.org\/10.1038\/nm.4106.","journal-title":"Nat Med"},{"key":"1978_CR19","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1006\/faat.1996.0056","volume":"30","author":"PM Garrison","year":"1996","unstructured":"Garrison PM, et al. Species-specific recombinant cell lines as bioassay systems for the detection of 2,3,7,8-tetrachlorodibenzo-p-dioxin-like chemicals. Fundam Appl Toxicol. 1996;30:194\u2013203.","journal-title":"Fundam Appl Toxicol"},{"key":"1978_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"1978_CR21","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.4049\/jimmunol.1701734","volume":"201","author":"R Aoki","year":"2018","unstructured":"Aoki R, Aoki-Yoshida A, Suzuki C, Takayama Y. Indole-3-pyruvic acid, an aryl hydrocarbon receptor activator, suppresses experimental colitis in mice. J Immunol. 2018;201:3683\u201393.","journal-title":"J Immunol"},{"key":"1978_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/nu13010228","author":"L Wu","year":"2021","unstructured":"Wu L, et al. Altered gut microbial metabolites in amnestic mild cognitive impairment and Alzheimer\u2019s disease: signals in host-microbe interplay. Nutrients. 2021;13:228. https:\/\/doi.org\/10.3390\/nu13010228.","journal-title":"Nutrients"},{"key":"1978_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000530907","volume":"22","author":"J Garcia Castro","year":"2023","unstructured":"Garcia Castro J, et al. CSF A\u03b240 levels do not correlate with the clinical manifestations of Alzheimer\u2019s disease. Neurodegener Dis. 2023;22:151\u20138.","journal-title":"Neurodegener Dis"},{"issue":"1","key":"1978_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13195-019-0481-4","volume":"11","author":"A Boumenir","year":"2019","unstructured":"Boumenir A, et al. CSF level of \u03b2-amyloid peptide predicts mortality in Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11:29.","journal-title":"Alzheimers Res Ther"},{"key":"1978_CR25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3233\/JAD-230524","volume":"96","author":"J Utz","year":"2023","unstructured":"Utz J, et al. Reconceptualization of the Erlangen score for the assessment of dementia risk: the ERlangen score. J Alzheimers Dis. 2023;96:265\u201375.","journal-title":"J Alzheimers Dis"},{"key":"1978_CR26","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1074\/jbc.M113.510131","volume":"289","author":"N Matsumura","year":"2014","unstructured":"Matsumura N, et al. \u03b3-Secretase associated with lipid rafts: multiple interactive pathways in the stepwise processing of \u03b2-carboxyl-terminal fragment. J Biol Chem. 2014;289:5109\u201321.","journal-title":"J Biol Chem"},{"key":"1978_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103449","author":"Y Yang","year":"2020","unstructured":"Yang Y, Chan WK. Selective autophagy maintains the Aryl Hydrocarbon Receptor Levels in HeLa cells: a mechanism that is dependent on the p23 co-chaperone. Int J Mol Sci. 2020;21:3449. https:\/\/doi.org\/10.3390\/ijms21103449.","journal-title":"Int J Mol Sci"},{"key":"1978_CR28","doi-asserted-by":"publisher","first-page":"44945","DOI":"10.1074\/jbc.M407986200","volume":"279","author":"KS Vetrivel","year":"2004","unstructured":"Vetrivel KS, et al. Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. J Biol Chem. 2004;279:44945\u201354.","journal-title":"J Biol Chem"},{"key":"1978_CR29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 2015;14:388\u2013405.","journal-title":"Lancet Neurol"},{"key":"1978_CR30","doi-asserted-by":"publisher","first-page":"1421346","DOI":"10.3389\/fimmu.2024.1421346","volume":"15","author":"F Bahman","year":"2024","unstructured":"Bahman F, et al. Aryl hydrocarbon receptor: current perspectives on key signaling partners and immunoregulatory role in inflammatory diseases. Front Immunol. 2024;15:1421346.","journal-title":"Front Immunol"},{"key":"1978_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41423-020-00585-5","volume":"18","author":"A Barroso","year":"2021","unstructured":"Barroso A, Mahler JV, Fonseca-Castro PH, Quintana FJ. The aryl hydrocarbon receptor and the gut\u2013brain axis. Cell Mol Immunol. 2021;18:259\u201368.","journal-title":"Cell Mol Immunol"},{"key":"1978_CR32","doi-asserted-by":"publisher","first-page":"105314","DOI":"10.1016\/j.phrs.2020.105314","volume":"164","author":"T Doifode","year":"2021","unstructured":"Doifode T, et al. The impact of the microbiota-gut-brain axis on Alzheimer\u2019s disease pathophysiology. Pharmacol Res. 2021;164:105314.","journal-title":"Pharmacol Res"},{"key":"1978_CR33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00109-023-02289-5","volume":"101","author":"A Salminen","year":"2023","unstructured":"Salminen A. Activation of aryl hydrocarbon receptor (AhR) in Alzheimer\u2019s disease: role of tryptophan metabolites generated by gut host-microbiota. J Mol Med (Berl). 2023;101:201\u201322.","journal-title":"J Mol Med (Berl)"},{"key":"1978_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23323-4","volume":"8","author":"V Rothhammer","year":"2018","unstructured":"Rothhammer V, et al. Detection of aryl hydrocarbon receptor agonists in human samples. Sci Rep. 2018;8:4970.","journal-title":"Sci Rep"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-01978-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-01978-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-01978-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:38:53Z","timestamp":1781631533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-01978-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1978"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-01978-w","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study protocol (Nr. 19_426_1-B) was approved by the Ethics Committee of the University of Erlangen-Nuremberg, which granted a waiver of informed consent, ensuring compliance with ethical standards while allowing comprehensive data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}